Related Experiment Video
Updated: Jun 23, 2026
04:22
Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Biomarkers for Alzheimer's disease
Ernest K J Pauwels1, Duccio Volterrani, Giuliano Mariani
1Leiden University Medical Center, Leiden, The Netherlands. ernestpauwels@gmail.com
Drug News & Perspectives
|May 15, 2009
Summary
Early detection of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) is crucial for timely therapeutic intervention. Biomarkers like cerebrospinal fluid (CSF) amyloid beta 42 (Abeta(42)) and tau, along with brain imaging, aid in diagnosing prodromal AD.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Medical Imaging
Background:
- Mild cognitive impairment (MCI) can progress to Alzheimer's disease (AD), necessitating early detection for therapeutic intervention.
- Amyloid beta peptide 42 (Abeta(42)) is a key pathological hallmark of AD.
- Cerebrospinal fluid (CSF) and brain imaging are critical for identifying prodromal AD.
Purpose of the Study:
- To summarize key diagnostic markers for Alzheimer's disease based on published knowledge.
- To discuss the utility of these markers in monitoring treatment efficacy.
- To explore the role of these markers in drug development and evaluation.
Main Methods:
- Analysis of cerebrospinal fluid (CSF) biomarkers, including Abeta(42) and phosphorylated tau.
- Utilizing structural and functional brain imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET).
- Evaluating imaging markers like reduced brain and hippocampus volume, and regional hypometabolism.
Main Results:
- CSF Abeta(42) and tau parameters demonstrate high sensitivity and specificity (>80%) for AD detection.
- Brain imaging reveals markers such as diminished global brain volume, hippocampal atrophy, and mediotemporal grey matter loss.
- Functional imaging shows neuronal disconnections and regional hypometabolism in AD patients.
Conclusions:
- Combined CSF biomarkers and advanced imaging techniques offer robust diagnostic capabilities for prodromal AD.
- These diagnostic markers hold significant potential for monitoring therapeutic responses and guiding the development of novel AD drugs.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.